Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evorpacept + Enfortumab Vedotin in Urothelial Carcinoma
NCT05524545Phase 1Completed
- Sponsor
- ALX Oncology
- Start
- Nov 2022
- Primary completion
- Jun 2025
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of evorpacept in urothelial carcinoma (UC), sponsored by ALX Oncology. Primary endpoints: First Cycle Dose Limiting Toxicities at 28 days, Adverse Events at 24 months and 1 more. Started Nov 2022; status: completed.
02
Drugs
evorpacept
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT05524545.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05524545.